Editorial: Treatment response and resistance to targeted therapies for NSCLC
Open Access
- 26 March 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyJournal of Clinical Oncology, 2024
- Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLCNew England Journal of Medicine, 2024
- Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLCNew England Journal of Medicine, 2023
- First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung CancerNew England Journal of Medicine, 2020
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020